Severe Gastritis after Administration of Nivolumab and Ipilimumab

Immune checkpoint inhibitors such as ipilimumab, a cytotoxic T-lymphocyte-associated antigen-4 inhibitor, have been widely used for advanced malignancies. As these inhibitors improve antitumor immunity via T-cell modulation, immune-mediated adverse events associated with T-cell activation, such as c...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishimura, Yoshito, Yasuda, Miho, Ocho, Kazuki, Iwamuro, Masaya, Yamasaki, Osamu, Tanaka, Takehiro, Otsuka, Fumio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6120399/
https://www.ncbi.nlm.nih.gov/pubmed/30186138
http://dx.doi.org/10.1159/000491862

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6120399/
https://www.ncbi.nlm.nih.gov/pubmed/30186138
http://dx.doi.org/10.1159/000491862

Ejemplares similares